Correction to: Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: Rationale with Focus on Concizumab
- PMID: 29931593
- PMCID: PMC6828249
- DOI: 10.1007/s40265-018-0933-3
Correction to: Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: Rationale with Focus on Concizumab
Abstract
Mechanisms of action of monoclonal antibodies against tissue factor pathway inhibitor (TFPI).
Erratum for
-
Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: Rationale with Focus on Concizumab.Drugs. 2018 Jun;78(9):881-890. doi: 10.1007/s40265-018-0922-6. Drugs. 2018. PMID: 29845491 Free PMC article. Review.
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
